Source-grounded facts extracted from Zymeworks Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Zymeworks Inc. reported financial results for the first quarter March 31, 2026 (three months ended March 31, 2026).
“On May 7, 2026, Zymeworks Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026.”
Zymeworks Inc. entered into Loan Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).
“Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).”
Zymeworks Inc. entered into Sale Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).
“On March 2, 2026, Zymeworks BC Inc. (“ Zymeworks BC ”), a subsidiary of Zymeworks Inc. (the “ Company ”), entered into a sale agreement (the “ Sale Agreement ”) with Zymeworks Royalty Limited Partnership (the “ Subsidiary ”), a special purpose entity newly formed by Zymeworks BC and by its general partner Zymeworks General Partner ULC (“ Zymeworks GP ”), the Company solely for the purpose of certain indemnification provisions thereunder, and Royalty Pharma Development Funding, LLC (“ Royalty Pharma ”) as administrative agent.”
Zymeworks Inc. incurred term loan of $250.0 million with Royalty Pharma Development Funding, LLC at fixed rate maturing December 31, 2042.
“Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).”
Oleg Nodelman was appointed as Director at Zymeworks Inc..
“appointed Mr. Oleg Nodelman, Founder and Portfolio Manager of EcoR1 (as defined below), as a director of the Company, effective as of February 17, 2025.”
Hollings C. Renton resigned as Director at Zymeworks Inc..
“Mr. Hollings C. Renton submitted his resignation from the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), including as chair and member of the Board’s compensation committee, effective December 10, 2024”
Kenneth Galbraith resigned as interim Chief Financial Officer at Zymeworks Inc..
“On August 30, 2024, Mr. Kenneth Galbraith resigned from the positions of interim Chief Financial Officer and as principal financial officer and principal accounting officer of the Company, effective as of the Start Date.”
Leone Patterson was appointed as Executive Vice President, Chief Business Officer and Chief Financial Officer at Zymeworks Inc..
“the Company’s board of directors (the “Board”) appointed Ms. Leone Patterson, age 61, as Executive Vice President, Chief Business Officer and Chief Financial Officer of the Company, effective upon her commencement of employment with the Company, which was anticipated to be September 1, 2024.”
Leone Patterson was appointed as Executive Vice President, Chief Business Officer and Chief Financial Officer at Zymeworks Inc..
“On July 19, 2024, the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) appointed Ms. Leone Patterson, age 61, as Executive Vice President, Chief Business Officer and Chief Financial Officer of the Company, effective upon her commencement of employment with the Company, which is anticipated to be September 1, 2024”
Zymeworks Inc. reported three months ended March 31, 2024 results: revenue $10.0 million.
“Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.”
Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..
“As previously reported, effective March 31, 2024 (the “Separation Date”), Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer.”
Kenneth Galbraith was appointed as interim Chief Financial Officer at Zymeworks Inc..
“the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.”
Dr. Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..
“On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.”
Dr. Neil Gallagher was appointed as director at Zymeworks Inc..
“On March 27, 2024, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Board, appointed Dr. Neil Gallagher as a director of the Company, effective as of April 2, 2024.”
Zymeworks Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended December 31, 2023.”
Scott Platshon was appointed as director at Zymeworks Inc..
“appointed Mr. Scott Platshon, Partner of EcoR1 (as defined below), as a director of the Company, effective as of February 22, 2024.”
Kenneth Hillan resigned as Director at Zymeworks Inc..
“Dr. Kenneth Hillan submitted his resignation from the Board, including as chair and member of the nominating and corporate governance committee and as member of the research and development committee of the Board, effective February 8, 2024.”
Alessandra Cesano was appointed as Director at Zymeworks Inc..
“appointed Dr. Alessandra Cesano as a director of the Company, effective as of February 8, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.